Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.
Cancer. 2012 Feb 1;118(3):681-8. doi: 10.1002/cncr.26323. Epub 2011 Jun 30.
Endometrial cancer (EC) is the most common extraintestinal malignancy in Lynch syndrome (LS) and often is the sentinel malignancy, yet there is no consensus regarding LS-EC detection algorithms. In this study, the authors determined the efficacy of family/personal history and tumor morphology in predicting LS in a cohort of patients with EC who had mutation-proven LS.
Amsterdam II (AmII) criteria, revised Bethesda guidelines (rBG), and Society of Gynecologic Oncologists (SGO) clinical screening criteria were applied to the pedigrees of 76 patients with mutation-proven LS who had pathology-proven EC. When tumors were tested for microsatellite instability (MSI) phenotype status or mismatch-repair protein-immunohistochemical (MMR-IHC) expression, those results also were reviewed, and LS-associated histopathologic features were documented in 38 available patients.
Of 76 patients, 36%, 58%, 71%, and 93% would have been selected for further testing for LS by pedigree screening at the time of EC diagnosis with rBG, AmII, SGO 20%-to-25%, and SGO 5%-to-10% criteria, respectively. Ninety percent (18 of 20 tumors) of tested ECs had high MSI, and 96% (22 of 23 tumors) had abnormal MMR-IHC expression. At least 1 LS-EC morphologic feature was present in 16 of 38 tumors (42%).
Clinical screening criteria had variable efficacy for the identification of LS-associated EC, and SGO 5%-to-10% criteria performed best. Characteristic pathologic features were present in a minority of patients. Although a high proportion of LS-ECs had the MSI phenotype and were MMR deficient, the specificity of these tests and of clinical screening for LS in unselected patients with EC has been poorly described. Prospective studies to determine the optimal combination of these screening modalities are required.
子宫内膜癌(EC)是林奇综合征(LS)中最常见的肠外恶性肿瘤,通常是首发恶性肿瘤,但目前尚没有关于 LS-EC 检测算法的共识。在这项研究中,作者确定了家族/个人病史和肿瘤形态在预测经突变证实的 LS 患者 EC 队列中 LS 中的作用。
将阿姆斯特丹 II(AmII)标准、修订后的贝塞斯达指南(rBG)和妇科肿瘤学会(SGO)临床筛查标准应用于 76 名经突变证实的 LS 患者的家系,这些患者的病理结果证实患有 EC。当对肿瘤进行微卫星不稳定性(MSI)表型状态或错配修复蛋白免疫组织化学(MMR-IHC)表达检测时,也对这些结果进行了审查,并在 38 名可获得的患者中记录了与 LS 相关的组织病理学特征。
在 76 名患者中,rBG、AmII、SGO 20%-25%和 SGO 5%-10%标准分别在 EC 诊断时对家系进行筛查,将分别有 36%、58%、71%和 93%的患者被选择进行进一步的 LS 检测。90%(18/20 例)的 EC 检测出高度 MSI,96%(22/23 例)的肿瘤存在 MMR-IHC 表达异常。在 38 例肿瘤中,至少有 1 例出现 LS-EC 形态学特征(42%)。
临床筛查标准对识别 LS 相关 EC 的效果各不相同,SGO 5%-10%标准效果最好。少数患者存在特征性的病理特征。尽管大多数 LS-EC 具有 MSI 表型且 MMR 缺失,但这些检测以及在未经选择的 EC 患者中进行 LS 的临床筛查的特异性尚未得到充分描述。需要进行前瞻性研究以确定这些筛查方法的最佳组合。